Intramedullary Spinal Cord Metastasis From Oligometastatic Melanoma of Unknown Primary Treated With Stereotactic Body Radiotherapy.
- 1Radiation Oncology, BC Cancer - Kelowna, Kelowna, CAN.
Abstract
Intramedullary spinal cord metastasis (ISCM) is an uncommon and challenging clinical entity with no established consensus regarding its optimal management. A 37-year-old female presented with left-sided facial numbness, right leg paresthesia with decreased temperature sensation, and right lower extremity weakness. Investigations demonstrated two intracranial lesions and an ISCM at T10 to T11. Biopsy of the intracranial lesion confirmed melanoma. The patient was treated with stereotactic body radiotherapy (SBRT) to a dose of 30 Gy in 5 fractions to the ISCM and stereotactic radiosurgery to a dose of 20 Gy in a single fraction to the intracranial metastases. The spinal cord dose received by a 0.035 cc volume was limited to less than or equal to 30 Gy. No spinal cord planning organ-at-risk volume was used. SBRT was followed by combination ipilimumab and nivolumab for four cycles, then maintenance nivolumab thereafter. At 25 months post-SBRT, the treated lesions decreased in size. There were no severe acute or late radiation-related toxicities, and the patient remained fully ambulatory from presentation to last follow-up.
Related
- Surgical resection versus stereotactic body radiotherapy for oligometastatic breast cancer to the liver.
- Spontaneous Pneumothorax During Stereotactic Body Radiotherapy for Pulmonary Metastasis From Osteosarcoma: A Case Report and Literature Review
- Prognostic stratification by the ESTRO/EORTC oligometastatic classification and simplified binary approaches in lung cancer patients treated with stereotactic ablative radiotherapy.
- Metastasis-directed radiotherapy (MDRT) for men with de novo, oligometastatic prostate cancer treated with long-term androgen deprivation therapy in the STAMPEDE trial (METANOVA): protocol for a multicentre, phase II randomised controlled trial in the USA
- Addition of Metastasis-Directed Therapy to Standard of Care for Oligometastatic Disease: Primary Aggregated Analysis of All Baskets from the Phase II Randomized EXTEND Trial
BibTeX
@article{aguirremeneses2026intramedullary,
title = {{Intramedullary Spinal Cord Metastasis From Oligometastatic Melanoma of Unknown Primary Treated With Stereotactic Body Radiotherapy.}},
author = {Karen Anne Aguirre-Meneses and Justin Owen and Benjamin Mou},
journal = {Cureus},
year = {2026},
month = sep,
doi = {10.7759/cureus.116732},
url = {https://europepmc.org/article/MED/42924288},
note = {CC BY},
}
RIS
TY - JOUR
TI - Intramedullary Spinal Cord Metastasis From Oligometastatic Melanoma of Unknown Primary Treated With Stereotactic Body Radiotherapy.
AU - Karen Anne Aguirre-Meneses
AU - Justin Owen
AU - Benjamin Mou
PY - 2026
DA - 2026/09/22
JO - Cureus
DO - 10.7759/cureus.116732
UR - https://europepmc.org/article/MED/42924288
AB - Intramedullary spinal cord metastasis (ISCM) is an uncommon and challenging clinical entity with no established consensus regarding its optimal management. A 37-year-old female presented with left-sided facial numbness, right leg paresthesia with decreased temperature sensation, and right lower extremity weakness. Investigations demonstrated two intracranial lesions and an ISCM at T10 to T11. Biopsy of the intracranial lesion confirmed melanoma. The patient was treated with stereotactic body radiotherapy (SBRT) to a dose of 30 Gy in 5 fractions to the ISCM and stereotactic radiosurgery to a dose of 20 Gy in a single fraction to the intracranial metastases. The spinal cord dose received by a 0.035 cc volume was limited to less than or equal to 30 Gy. No spinal cord planning organ-at-risk volume was used. SBRT was followed by combination ipilimumab and nivolumab for four cycles, then maintenance nivolumab thereafter. At 25 months post-SBRT, the treated lesions decreased in size. There were no severe acute or late radiation-related toxicities, and the patient remained fully ambulatory from presentation to last follow-up.
SN - 2168-8184
ER -